TY - JOUR
T1 - Mechanochemical endovenous ablation of small saphenous vein insufficiency using the clarivein® device
T2 - One-year results of a prospective series
AU - Boersma, D.
AU - van Eekeren, R.R.J.P.
AU - Werson, D.A.B.
AU - van der Waal, R.I.F.
AU - Reijnen, M.M.J.P.
AU - de Vries, J.-P.P.M.
PY - 2013/3/1
Y1 - 2013/3/1
N2 - Objective: This study evaluated the feasibility, safety and 1-year results of mechanochemical endovenous ablation (MOCA™) of small saphenous vein (SSV) insufficiency. Design: Prospective cohort study. Materials and methods: Fifty consecutive patients were treated for primary SSV insufficiency with MOCA™ using the ClariVein® device and polidocanol. Initial technical success, complications, patient satisfaction and visual analogue scale (VAS) pain score were assessed. Anatomic and clinical success was assessed at 6 weeks and at 1 year. Results: Initial technical success of MOCA™ was 100%. At the 6-week assessment, all treated veins were occluded. The 1-year follow-up duplex showed anatomic success in 94% (95% confidence interval, 0.87-1). Venous clinical severity score (VCSS) decreased significantly from 3.0 (interquartile range (IQR) 2-5) before treatment to 1.0 (IQR 1-3, P < 0.001) at 6 weeks and to 1.0 (IQR 1-2, P < 0.001) at 1 year. Median procedural VAS score for pain was 2 (IQR 2-4). No major complications were observed, especially no nerve injury. Conclusions: MOCA™ is a safe, feasible and efficacious technique for treatment of SSV insufficiency. One-year follow-up shows a 94% anatomic success rate and no major complications.
AB - Objective: This study evaluated the feasibility, safety and 1-year results of mechanochemical endovenous ablation (MOCA™) of small saphenous vein (SSV) insufficiency. Design: Prospective cohort study. Materials and methods: Fifty consecutive patients were treated for primary SSV insufficiency with MOCA™ using the ClariVein® device and polidocanol. Initial technical success, complications, patient satisfaction and visual analogue scale (VAS) pain score were assessed. Anatomic and clinical success was assessed at 6 weeks and at 1 year. Results: Initial technical success of MOCA™ was 100%. At the 6-week assessment, all treated veins were occluded. The 1-year follow-up duplex showed anatomic success in 94% (95% confidence interval, 0.87-1). Venous clinical severity score (VCSS) decreased significantly from 3.0 (interquartile range (IQR) 2-5) before treatment to 1.0 (IQR 1-3, P < 0.001) at 6 weeks and to 1.0 (IQR 1-2, P < 0.001) at 1 year. Median procedural VAS score for pain was 2 (IQR 2-4). No major complications were observed, especially no nerve injury. Conclusions: MOCA™ is a safe, feasible and efficacious technique for treatment of SSV insufficiency. One-year follow-up shows a 94% anatomic success rate and no major complications.
KW - Polidocanol
KW - Saphenous vein
KW - Varicose veins
KW - Varicose veins therapy
UR - https://www.scopus.com/pages/publications/84874529896
U2 - 10.1016/j.ejvs.2012.12.004
DO - 10.1016/j.ejvs.2012.12.004
M3 - Article
C2 - 23312507
AN - SCOPUS:84874529896
SN - 1078-5884
VL - 45
SP - 299
EP - 303
JO - European journal of vascular and endovascular surgery
JF - European journal of vascular and endovascular surgery
IS - 3
ER -